LAG3 and neoplasm: In contrast, M-MDSC and PMN-MDSC rapidly dropped after the first treatment cycle, indicating a direct activity of LAG3/PD-1 blocking on the systemic myeloid population rather than an indirect effect due to the reduced tumor burden.